Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure

NCT02681952 is registered in ClinicalTrials.gov with Daewon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02681952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02681952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure
Lead sponsor
Daewon Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2015
Completion date
December 31, 2016
Enrollment
153 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure